Heitor Siffert P. de Souza

Heitor Siffert P. de Souza


Our research group has a broad background in gastroenterology, with specific training and expertise in intestinal diseases. Nevertheless, the research includes also esophageal, gastric, liver, and pancreatic diseases, ranging from basic to clinical science.

We are interested in basically all aspects of gastrointestinal diseases, mechanisms of disease, and novel therapies, with a special attention to intestinal diseases. In particular, our group investigates mechanisms of inflammatory disorders of the gastrointestinal tract, with focus on inflammatory bowel disease (IBD). Our experimental approaches involve a combination of epidemiological investigation, clinical studies with IBD patients, in addition to molecular, cellular and animal models.

Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; mucosal immunity; inflammation; carcinogenesis; epidemiology of gastrointestinal diseases.


MD, School of Medicine, Federal University of Rio de Janeiro, UFRJ, Brazil.

PhD in Clinical Medicine, Federal University of Rio de Janeiro, UFRJ, Brazil, with collaborative period in Barts and The London Queen Mary's School of Medicine and Dentistry, London, UK.

Postdoctoral Fellowship, Cleveland Clinic Foundation, Cleveland, Ohio, USA.





Best original work - Solvay/AIGE Award of Gastroenterology and Hepatology, Panamerican Congress of Gastroenterology, Vancouver, Canada (1999)

GEDIIB – Brazilian Study Group for Inflammatory Bowel Disease (2007-present)

Member of the Brazilian Federation of Gastroenterology (FBG) (2014-present)

American Gastroenterological Association Fellow (AGAF) (2015-present)

Active member of the BRICS IBD consortium Governing Board (2019-present)

Selected Publications

Pêgo B, Martinusso CA, Bernardazzi C, Ribeiro BE, de Araujo Cunha AF, de Souza Mesquita J, Nanini HF, Machado MP, Castelo-Branco MTL, Cavalcanti MG, de Souza HSP. Schistosoma mansoni Coinfection Attenuates Murine Toxoplasma gondii-Induced Crohn’s-Like Ileitis by Preserving the Epithelial Barrier and Downregulating the Inflammatory Response. Front Immunol. 2019 Mar 18;10:442.
doi: 10.3389/fimmu.2019.00442 eCollection 2019.

de Souza HSP, Fiocchi C. Network Medicine: A Mandatory Next Step for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Mar 19;24(4):671-679.
doi: 10.1093/ibd/izx111

de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):739-749.
doi: 10.1038/nrgastro.2017.110

de S B Fróes R, Carvalho ATP, de V Carneiro AJ, de Barros Moreira AMH, Moreira JPL, Luiz RR, de Souza HS. The socio-economic impact of work disability due to inflammatory bowel disease in Brazil. Eur J Health Econ. 2018 Apr;19(3):463-470.
doi: 10.1007/s10198-017-0896-4

Rapozo DC, Bernardazzi C, de Souza HS. Diet and microbiota in inflammatory bowel disease: The gut in disharmony. World J Gastroenterol. 2017 Mar 28;23(12):2124-2140.
doi: 10.3748/wjg.v23.i12.2124

Related News
More Content